気管支痙攣治療薬市場：治療タイプ、投与経路、エンドユーザー別-2025-2030年の世界予測

気管支痙攣治療薬市場は、2023年に2億9,681万米ドルと評価され、2024年には3億972万米ドルに達すると予測され、CAGR 4.38%で成長し、2030年には4億77万米ドルに達すると予測されています。

気管支痙攣治療薬市場には、喘息や慢性閉塞性肺疾患（COPD）などに特徴的な気道の狭窄を緩和することを目的としたさまざまなソリューションが含まれます。治療の選択肢は、気管支拡張剤やコルチコステロイドのような医薬品による介入から、新たな生物学的製剤や可能性のある統合療法まで多岐にわたる。これらの治療の必要性は、大気汚染、喫煙習慣、遺伝的素因などの要因による呼吸器疾患の世界の有病率の増加によって高まっています。気管支痙攣治療の応用は、予防医療と患者の生活の質を向上させるための急性増悪の管理の両方にとって重要です。最終用途の設定には病院、診療所、外来診療が含まれる一方、携帯用吸入装置の進歩により在宅治療も普及しています。市場の主な成長要因としては、ドラッグデリバリーシステムにおける技術革新、支持的なヘルスケア政策、新興国におけるヘルスケアインフラの拡大などが挙げられます。個別化医療のアプローチや、気管支痙攣に関与する特定の経路を標的とした新規治療法の開発には、大きな潜在的機会があります。しかし、研究開発コストの高さ、規制要件の厳しさ、ジェネリック医薬品の普及がブランド医薬品の収益を圧迫していることが、市場成長の課題となっています。さらに、複雑な治療レジメンによる患者のコンプライアンス問題もハードルとなっています。成長を生かすために、企業はリマインダーやリアルタイムのモニタリングを通じて患者のアドヒアランスを向上させるデジタルヘルスソリューションなどの分野でイノベーションを起こしたり、より効率的な吸入メカニズムの研究開発に投資したりすることが考えられます。ハイテク企業とのコラボレーションにより、治療の個別化や患者の反応パターンに関するデータに基づく洞察が強化される可能性があります。競合情勢にもかかわらず、研究開発と流通に焦点を当てた戦略的パートナーシップとともに、手頃な価格で利用しやすい治療に焦点を当てることで、持続的な競争力を提供し、市場の拡大を促進することができます。

市場力学：急速に進化する気管支痙攣治療薬市場の主要市場インサイトを公開

気管支痙攣治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 喘息とCOPDの世界の有病率の上昇
  • 政府支出およびヘルスケアへの取り組みの増加
  • 気管支痙攣とその健康への影響に関する意識の高まり
• 市場抑制要因
  • 治療に伴う高額な費用と医薬品の発売に関する厳しい規制
• 市場機会
  • 製薬会社と研究機関との戦略的提携
  • 吸入デバイス、ネブライザー、気管支痙攣治療における技術革新
• 市場の課題
  • 気管支痙攣治療に伴う副作用

ポーターの5つの力：気管支痙攣治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：気管支痙攣治療薬市場における外部からの影響の把握

外部マクロ環境要因は、気管支痙攣治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析気管支痙攣治療薬市場における競合情勢の把握

気管支痙攣治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス気管支痙攣治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、気管支痙攣治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨気管支痙攣治療薬市場における成功への道筋を描く

気管支痙攣治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 喘息とCOPDの罹患率が世界的に上昇
    • 政府支出とヘルスケア対策の拡大
    • 気管支痙攣とその健康への影響に関する認識の高まり
  • 抑制要因
    • 治療にかかる高額な費用と薬物放出に関する厳しい規制
  • 機会
    • 製薬企業と調査機関の戦略的パートナーシップ
    • 吸入器、ネブライザー、気管支痙攣治療における革新
  • 課題
    • 気管支痙攣治療に伴う副作用
• 市場セグメンテーション分析
  • 治療の種類：患者の生活の質を向上させるために、即時の緩和と長期管理のための薬剤の使用が増加しています。
  • エンドユーザー：利便性とメンテナンスの容易さから、在宅ケア環境を好む消費者
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 気管支痙攣治療薬市場治療の種類別

• 医薬品
  • 気管支拡張薬
  • コルチコステロイド
  • ロイコトリエン修飾薬
  • 肥満細胞安定剤
  • メチルキサンチン
• 非薬物療法
  • 酸素療法
  • 呼吸リハビリテーション

第7章 気管支痙攣治療薬市場：投与経路別

• 吸入
• 静脈内
• オーラル
• 皮下

第8章 気管支痙攣治療薬市場：エンドユーザー別

• 外来手術センター
• ホームケア設定
• 病院・クリニック
• 調査・学術機関

第9章 南北アメリカの気管支痙攣治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の気管支痙攣治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの気管支痙攣治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ヴェローナファーマのオトゥヴァイレが初の新規吸入COPD治療としてFDAの承認を取得
  • ビアトリスとキンデバは、喘息とCOPDの治療へのアクセスを向上させるため、FDA承認のジェネリックSymbicort、Breynaを発売しました。
• 戦略分析と提言

企業一覧

• 1. Amphastar Pharmaceuticals, Inc
• 2. Bayer AG
• 3. C.H. Boehringer Sohn AG & Co. KG
• 4. CHIESI Farmaceutici S.p.A.
• 5. Cipla Limited
• 6. GlaxoSmithKline plc
• 7. Grifols, S.A.
• 8. Lybrate, Inc.
• 9. Merck KGaA
• 10. Novartis AG
• 11. Orion Corporation
• 12. Pfizer Inc
• 13. Temple University Health System, Inc.
• 14. Teva Pharmaceutical Industries Ltd
• 15. Vectura Group Ltd by Philip Morris International Inc.
• 16. Viatris Inc.

LIST OF FIGURES

• FIGURE 1. BRONCHIAL SPASMS TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BRONCHIAL SPASMS TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BRONCHIAL SPASMS TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MAST CELL STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PULMONARY REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 47. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 48. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 74. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 75. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 78. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 79. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 80. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 163. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 165. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 166. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 185. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 186. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 188. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 190. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 191. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 238. BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 239. BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Bronchial Spasms Treatment Market was valued at USD 296.81 million in 2023, expected to reach USD 309.72 million in 2024, and is projected to grow at a CAGR of 4.38%, to USD 400.77 million by 2030.

The market for bronchial spasms treatment encompasses a variety of solutions aimed at alleviating the constriction of airways characteristic of conditions such as asthma and chronic obstructive pulmonary disease (COPD). Treatment options range from pharmaceutical interventions-like bronchodilators and corticosteroids-to emerging biologics and possible integrative therapies. The necessity of these treatments is heightened by the increasing global prevalence of respiratory ailments due to factors such as air pollution, smoking habits, and genetic predispositions. Applications of bronchial spasm treatments are critical for both preventative care and the management of acute exacerbations to improve patient quality of life. End-use settings include hospitals, clinics, and outpatient services, while home-based treatments also gain traction with advancements in portable inhalation devices. Key growth influencers in the market include technological innovations in drug delivery systems, supportive healthcare policies, and the growing healthcare infrastructure in emerging economies. Significant potential opportunities lie in personalized medicine approaches and the development of novel therapies targeting specific pathways involved in bronchial spasms. However, market growth is challenged by high R&D costs, stringent regulatory requirements, and the prevalence of generic alternatives dampening brand-name revenues. Additionally, patient compliance issues due to complex treatment regimens present hurdles. To capitalize on growth, firms could innovate in areas such as digital health solutions that ensure better patient adherence through reminders and real-time monitoring, or invest in R&D for more efficient inhaler mechanisms. Collaboration with tech companies could enhance treatment personalization and data-based insights into patient response patterns. Despite the competitive landscape, a focus on affordable and accessible treatments, along with strategic partnerships focusing on R&D and distribution, can provide a sustained competitive edge and foster market expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchial Spasms Treatment Market

The Bronchial Spasms Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of asthma and COPD globally
  • Increasing government spending and healthcare initiatives
  • Growing awareness regarding bronchial spasms and their impact on health
• Market Restraints
  • High costs associated with treatment and stringent regulations regarding the release of drugs
• Market Opportunities
  • Strategic partnerships between pharma companies and research institutions
  • Innovations in inhaler devices, nebulizers, and bronchial spasm treatment
• Market Challenges
  • Adverse effects associated with bronchial spasms treatments

Porter's Five Forces: A Strategic Tool for Navigating the Bronchial Spasms Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchial Spasms Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchial Spasms Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchial Spasms Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchial Spasms Treatment Market

A detailed market share analysis in the Bronchial Spasms Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchial Spasms Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchial Spasms Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchial Spasms Treatment Market

A strategic analysis of the Bronchial Spasms Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchial Spasms Treatment Market, highlighting leading vendors and their innovative profiles. These include Amphastar Pharmaceuticals, Inc, Bayer AG, C.H. Boehringer Sohn AG & Co. KG, CHIESI Farmaceutici S.p.A., Cipla Limited, GlaxoSmithKline plc, Grifols, S.A., Lybrate, Inc., Merck KGaA, Novartis AG, Orion Corporation, Pfizer Inc, Temple University Health System, Inc., Teva Pharmaceutical Industries Ltd, Vectura Group Ltd by Philip Morris International Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bronchial Spasms Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Medications and Non-Pharmacological Treatments. The Medications is further studied across Bronchodilators, Corticosteroids, Leukotriene Modifiers, Mast Cell Stabilizers, and Methylxanthines. The Non-Pharmacological Treatments is further studied across Oxygen Therapy and Pulmonary Rehabilitation.
• Based on Route of Administration, market is studied across Inhalation, Intravenous, Oral, and Subcutaneous.
• Based on End User, market is studied across Ambulatory Surgical Centers, Homecare Settings, Hospitals & Clinics, and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of asthma and COPD globally
    • 5.1.1.2. Increasing government spending and healthcare initiatives
    • 5.1.1.3. Growing awareness regarding bronchial spasms and their impact on health
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with treatment and stringent regulations regarding the release of drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Strategic partnerships between pharma companies and research institutions
    • 5.1.3.2. Innovations in inhaler devices, nebulizers, and bronchial spasm treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with bronchial spasms treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Rising usage of medications for immediate relief and long-term management to improve patient quality of life
  • 5.2.2. End User: Consumer preference for homecare settings due to convenience and ease of maintenance
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Bronchial Spasms Treatment Market, by Treatment Type

• 6.1. Introduction
• 6.2. Medications
  • 6.2.1. Bronchodilators
  • 6.2.2. Corticosteroids
  • 6.2.3. Leukotriene Modifiers
  • 6.2.4. Mast Cell Stabilizers
  • 6.2.5. Methylxanthines
• 6.3. Non-Pharmacological Treatments
  • 6.3.1. Oxygen Therapy
  • 6.3.2. Pulmonary Rehabilitation

7. Bronchial Spasms Treatment Market, by Route of Administration

• 7.1. Introduction
• 7.2. Inhalation
• 7.3. Intravenous
• 7.4. Oral
• 7.5. Subcutaneous

8. Bronchial Spasms Treatment Market, by End User

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Homecare Settings
• 8.4. Hospitals & Clinics
• 8.5. Research & Academic Institutes

9. Americas Bronchial Spasms Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bronchial Spasms Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bronchial Spasms Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Verona Pharma ohtuvayre gains FDA approval as first novel inhaled COPD treatment
  • 12.3.2. Viatris and Kindeva launch FDA-approved generic Symbicort, Breyna, to enhance asthma and COPD treatment accessibility
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amphastar Pharmaceuticals, Inc
• 2. Bayer AG
• 3. C.H. Boehringer Sohn AG & Co. KG
• 4. CHIESI Farmaceutici S.p.A.
• 5. Cipla Limited
• 6. GlaxoSmithKline plc
• 7. Grifols, S.A.
• 8. Lybrate, Inc.
• 9. Merck KGaA
• 10. Novartis AG
• 11. Orion Corporation
• 12. Pfizer Inc
• 13. Temple University Health System, Inc.
• 14. Teva Pharmaceutical Industries Ltd
• 15. Vectura Group Ltd by Philip Morris International Inc.
• 16. Viatris Inc.